> top > docs > PubMed:17261671 > annotations

PubMed:17261671 JSONTXT

Annnotations TAB JSON ListView MergeView

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 101-329 DRI_Challenge denotes Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors involved in the transcriptional regulation of key metabolic pathways such as lipid metabolism, adipogenesis, and insulin sensitivity.
T2 330-483 DRI_Background denotes More recent work implicates all 3 PPAR isotypes (alpha, gamma, and delta, also known as beta or beta/delta) in inflammatory and atherosclerotic pathways.
T3 484-762 DRI_Approach denotes Because these nuclear receptors are activated by extracellular signals and control multiple gene targets, PPARs can be seen as nodes that control multiple inputs and outputs involved in energy balance, providing insight into how metabolism and the vasculature may be integrated.
T4 763-1079 DRI_Approach denotes The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis.
T5 1080-1256 DRI_Background denotes Together, these various observations have stimulated intense interest in PPARs as therapeutic targets and led to large-scale cardiovascular end-point trials with PPAR agonists.
T6 1257-1456 DRI_Background denotes The first of these studies has generated mixed results that require careful review, especially in anticipation of additional clinical trial data and ongoing attempts to develop novel PPAR modulators.
T7 1457-1660 DRI_Approach denotes Such analysis of the existing PPAR data, the appropriate use of currently approved PPAR agonists, and continued progress in PPAR therapeutics will be predicated on a better understanding of PPAR biology.

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-100 Sentence denotes Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
T2 101-329 Sentence denotes Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors involved in the transcriptional regulation of key metabolic pathways such as lipid metabolism, adipogenesis, and insulin sensitivity.
T3 330-483 Sentence denotes More recent work implicates all 3 PPAR isotypes (alpha, gamma, and delta, also known as beta or beta/delta) in inflammatory and atherosclerotic pathways.
T4 484-762 Sentence denotes Because these nuclear receptors are activated by extracellular signals and control multiple gene targets, PPARs can be seen as nodes that control multiple inputs and outputs involved in energy balance, providing insight into how metabolism and the vasculature may be integrated.
T5 763-1079 Sentence denotes The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis.
T6 1080-1256 Sentence denotes Together, these various observations have stimulated intense interest in PPARs as therapeutic targets and led to large-scale cardiovascular end-point trials with PPAR agonists.
T7 1257-1456 Sentence denotes The first of these studies has generated mixed results that require careful review, especially in anticipation of additional clinical trial data and ongoing attempts to develop novel PPAR modulators.
T8 1457-1660 Sentence denotes Such analysis of the existing PPAR data, the appropriate use of currently approved PPAR agonists, and continued progress in PPAR therapeutics will be predicated on a better understanding of PPAR biology.
T1 0-100 Sentence denotes Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
T2 101-329 Sentence denotes Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors involved in the transcriptional regulation of key metabolic pathways such as lipid metabolism, adipogenesis, and insulin sensitivity.
T3 330-483 Sentence denotes More recent work implicates all 3 PPAR isotypes (alpha, gamma, and delta, also known as beta or beta/delta) in inflammatory and atherosclerotic pathways.
T4 484-762 Sentence denotes Because these nuclear receptors are activated by extracellular signals and control multiple gene targets, PPARs can be seen as nodes that control multiple inputs and outputs involved in energy balance, providing insight into how metabolism and the vasculature may be integrated.
T5 763-1079 Sentence denotes The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis.
T6 1080-1256 Sentence denotes Together, these various observations have stimulated intense interest in PPARs as therapeutic targets and led to large-scale cardiovascular end-point trials with PPAR agonists.
T7 1257-1456 Sentence denotes The first of these studies has generated mixed results that require careful review, especially in anticipation of additional clinical trial data and ongoing attempts to develop novel PPAR modulators.
T8 1457-1660 Sentence denotes Such analysis of the existing PPAR data, the appropriate use of currently approved PPAR agonists, and continued progress in PPAR therapeutics will be predicated on a better understanding of PPAR biology.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 816-825 gene:5465 denotes PPARalpha
T1 1063-1078 disease:C0003850 denotes atherosclerosis
T2 816-825 gene:5465 denotes PPARalpha
T3 1063-1078 disease:C0004153 denotes atherosclerosis
T4 866-875 gene:5468 denotes PPARgamma
T5 1063-1078 disease:C0003850 denotes atherosclerosis
T6 866-875 gene:5468 denotes PPARgamma
T7 1063-1078 disease:C0004153 denotes atherosclerosis
T8 1020-1024 gene:5465 denotes PPAR
T9 1063-1078 disease:C0003850 denotes atherosclerosis
T10 1020-1024 gene:5465 denotes PPAR
T11 1063-1078 disease:C0004153 denotes atherosclerosis
R1 T0 T1 associated_with PPARalpha,atherosclerosis
R2 T2 T3 associated_with PPARalpha,atherosclerosis
R3 T4 T5 associated_with PPARgamma,atherosclerosis
R4 T6 T7 associated_with PPARgamma,atherosclerosis
R5 T8 T9 associated_with PPAR,atherosclerosis
R6 T10 T11 associated_with PPAR,atherosclerosis

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 1063-1078 HP_0002621 denotes atherosclerosis

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
17261671-4#53#62#gene5465 816-825 gene5465 denotes PPARalpha
17261671-4#103#112#gene5468 866-875 gene5468 denotes PPARgamma
17261671-4#300#315#diseaseC0003850 1063-1078 diseaseC0003850 denotes atherosclerosis
17261671-4#300#315#diseaseC0004153 1063-1078 diseaseC0004153 denotes atherosclerosis
17261671-4#300#315#diseaseC0003850 1063-1078 diseaseC0003850 denotes atherosclerosis
17261671-4#300#315#diseaseC0004153 1063-1078 diseaseC0004153 denotes atherosclerosis
53#62#gene5465300#315#diseaseC0003850 17261671-4#53#62#gene5465 17261671-4#300#315#diseaseC0003850 associated_with PPARalpha,atherosclerosis
53#62#gene5465300#315#diseaseC0004153 17261671-4#53#62#gene5465 17261671-4#300#315#diseaseC0004153 associated_with PPARalpha,atherosclerosis
53#62#gene5465300#315#diseaseC0003850 17261671-4#53#62#gene5465 17261671-4#300#315#diseaseC0003850 associated_with PPARalpha,atherosclerosis
53#62#gene5465300#315#diseaseC0004153 17261671-4#53#62#gene5465 17261671-4#300#315#diseaseC0004153 associated_with PPARalpha,atherosclerosis
103#112#gene5468300#315#diseaseC0003850 17261671-4#103#112#gene5468 17261671-4#300#315#diseaseC0003850 associated_with PPARgamma,atherosclerosis
103#112#gene5468300#315#diseaseC0004153 17261671-4#103#112#gene5468 17261671-4#300#315#diseaseC0004153 associated_with PPARgamma,atherosclerosis
103#112#gene5468300#315#diseaseC0003850 17261671-4#103#112#gene5468 17261671-4#300#315#diseaseC0003850 associated_with PPARgamma,atherosclerosis
103#112#gene5468300#315#diseaseC0004153 17261671-4#103#112#gene5468 17261671-4#300#315#diseaseC0004153 associated_with PPARgamma,atherosclerosis

DisGeNet-2017-sample

Id Subject Object Predicate Lexical cue
T1817 816-825 gene:5465 denotes PPARalpha
T1818 1063-1078 disease:C0003850 denotes atherosclerosis
T1819 866-875 gene:5468 denotes PPARgamma
R1 T1817 T1818 associated_with PPARalpha,atherosclerosis
R2 T1817 T1818 associated_with PPARalpha,atherosclerosis
R3 T1819 T1818 associated_with PPARgamma,atherosclerosis
R4 T1819 T1818 associated_with PPARgamma,atherosclerosis

sentences

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-100 Sentence denotes Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
TextSentencer_T2 101-329 Sentence denotes Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors involved in the transcriptional regulation of key metabolic pathways such as lipid metabolism, adipogenesis, and insulin sensitivity.
TextSentencer_T3 330-483 Sentence denotes More recent work implicates all 3 PPAR isotypes (alpha, gamma, and delta, also known as beta or beta/delta) in inflammatory and atherosclerotic pathways.
TextSentencer_T4 484-762 Sentence denotes Because these nuclear receptors are activated by extracellular signals and control multiple gene targets, PPARs can be seen as nodes that control multiple inputs and outputs involved in energy balance, providing insight into how metabolism and the vasculature may be integrated.
TextSentencer_T5 763-1079 Sentence denotes The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis.
TextSentencer_T6 1080-1256 Sentence denotes Together, these various observations have stimulated intense interest in PPARs as therapeutic targets and led to large-scale cardiovascular end-point trials with PPAR agonists.
TextSentencer_T7 1257-1456 Sentence denotes The first of these studies has generated mixed results that require careful review, especially in anticipation of additional clinical trial data and ongoing attempts to develop novel PPAR modulators.
TextSentencer_T8 1457-1660 Sentence denotes Such analysis of the existing PPAR data, the appropriate use of currently approved PPAR agonists, and continued progress in PPAR therapeutics will be predicated on a better understanding of PPAR biology.
T1 0-100 Sentence denotes Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
T2 101-329 Sentence denotes Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors involved in the transcriptional regulation of key metabolic pathways such as lipid metabolism, adipogenesis, and insulin sensitivity.
T3 330-483 Sentence denotes More recent work implicates all 3 PPAR isotypes (alpha, gamma, and delta, also known as beta or beta/delta) in inflammatory and atherosclerotic pathways.
T4 484-762 Sentence denotes Because these nuclear receptors are activated by extracellular signals and control multiple gene targets, PPARs can be seen as nodes that control multiple inputs and outputs involved in energy balance, providing insight into how metabolism and the vasculature may be integrated.
T5 763-1079 Sentence denotes The ongoing clinical use of fibrates, which activate PPARalpha, and thiazolidinediones, which activate PPARgamma, establishes these receptors as viable drug targets, whereas considerable in vitro animal model and human surrogate marker studies suggest that PPAR activation may limit inflammation and atherosclerosis.
T6 1080-1256 Sentence denotes Together, these various observations have stimulated intense interest in PPARs as therapeutic targets and led to large-scale cardiovascular end-point trials with PPAR agonists.
T7 1257-1456 Sentence denotes The first of these studies has generated mixed results that require careful review, especially in anticipation of additional clinical trial data and ongoing attempts to develop novel PPAR modulators.
T8 1457-1660 Sentence denotes Such analysis of the existing PPAR data, the appropriate use of currently approved PPAR agonists, and continued progress in PPAR therapeutics will be predicated on a better understanding of PPAR biology.

UBERON-AE

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 732-743 http://purl.obolibrary.org/obo/UBERON_0002049 denotes vasculature
PD-UBERON-AE-B_T2 1199-1204 http://purl.obolibrary.org/obo/UBERON_0002542 denotes scale

performance-test

Id Subject Object Predicate Lexical cue
PD-UBERON-AE-B_T1 732-743 http://purl.obolibrary.org/obo/UBERON_0002049 denotes vasculature
PD-UBERON-AE-B_T2 1199-1204 http://purl.obolibrary.org/obo/UBERON_0002542 denotes scale